Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia

Kathryn E Flynn, PhD, Kevin P. Weinfurt, PhD, Li Lin, MS, Jerald P. Radich, MD, Charles A. Schiffer, MD, Michael J. Mauro, MD, Javier Pinilla Ibarz, MD PhD, Joseph O. Moore, MD, Richard A. Larson, MD, Vivian G. Oehler, MD, Michael W. Deininger, James E. Thompson, MD, Neil P Shah, MD PhD, Martha Wadleigh, MD, Ellen K. Ritchie, MD, Richard T. Silver, MD, Jorge E. Cortes, MD, Vamsi Kota, Ehab L. Atallah, MD

Blood (2019) 134 (Supplement_1): 705.

https://doi.org/10.1182/blood-2019-126002

Published: 2019

Journal Articles

Recombinant Interferon-α Reduces Thrombotic Events in Patients with Polycythemia Vera

Spencer Krichevsky, BS, Ghaith Abu Zeinah, MD, Claudia Sosner, BA, Diana Jaber, BA, Niamh Savage, BA, Gabriela Hoberman, BA, Ellen K. Ritchie, MD, Andrew I. Schafer, MD, Richard T. Silver, MD, Joseph Scandura, MD PhD

Blood (2019) 134 (Supplement_1): 1664.

https://doi.org/10.1182/blood-2019-131605

Published: 2019

Journal Articles

Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib

Claire N Harrison, Professor, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Eric Jourdan, MD, Richard T. Silver, MD, Harry C Schouten, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Derek Tang, PhD BSPharm, Angela Hu, MS, EDM, Shien Guo, PhD, Weiqin Liao, MS, Carrie Brownstein, MD, Ruben A Mesa, MD

Blood (2019) 134 (Supplement_1): 2207.

https://doi.org/10.1182/blood-2019-129386

Published: 2019

Journal Articles

Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival

Ghaith Abu Zeinah, MD, Spencer Krichevsky, BS, Diana Jaber, BA, Niamh Savage, BA, Claudia Sosner, BA, Gabriela Hoberman, BA, Ellen K. Ritchie, MD, Andrew I. Schafer, MD, Joseph Scandura, MD PhD, Richard T. Silver, MD

Blood (2019) 134 (Supplement_1): 2942.

https://doi.org/10.1182/blood-2019-130265

Published: 2019

Journal Articles

Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings

Blood (2019) 134 (Supplement_1): 2943.

https://doi.org/10.1182/blood-2019-124865

Published: 2019

Journal Articles

Impact of Bone Marrow Fibrosis Grade in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis. a Study of the Mysec Group

Blood (2019) 134 (Supplement_1): 2946.

https://doi.org/10.1182/blood-2019-124854

Published: 2019

Journal Articles

Disease Phenotype and Clonal Amplification in Calreticulin del52 and ins5 Knock-in Mice Are Dependent on the Type of Mutations and Gene Dosage

Camélia Benlabiod, Maira da Costa Cacemiro, PhD, Thomas Balligand, MD, Barbara Panneau-Schmaltz, PhD, Delphine Muller, Laure Touchard, Patrick Gonin, DVM, Jean-Luc Villeval, PhD, Stefan N Constantinescu, MD PhD, Hana Raslova, PhD, William Vainchenker, MD PhD, Isabelle Plo, Caroline Marty, PhD

Blood (2019) 134 (Supplement_1): 311.

https://doi.org/10.1182/blood-2019-127918

Published: 2019

Journal Articles

Chitinase 3-like 1 Produced By Fibrocytes Promotes Myelofibrosis

Blood (2019) 134 (Supplement_1): 4197.

https://doi.org/10.1182/blood-2019-125525

Published: 2019

Journal Articles

Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX

Claire N Harrison, Professor, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Eric Jourdan, MD, Richard T. Silver, MD, Harry C Schouten, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Juan Shen, PhD, Tymara Berry, MD, Carrie Brownstein, MD, Ruben A Mesa, MD

Blood (2019) 134 (Supplement_1): 4165.

https://doi.org/10.1182/blood-2019-130069

Published: 2019

Journal Articles

Tet2 Deficiency in Macrophages Undermines Heart Repair after Infarction

Shaohai Fang, MS, Yang Xiao, PhD, Jia Li, PhD, Tingting Li, MD, Hongxiang Zeng, PhD, Wei Han, MS, Yubin Zhou, PhD, Deqiang Sun, PhD, James M. Martin, MD, Yun Huang, PhD

Blood (2018) 132 (Supplement 1): 2394.

https://doi.org/10.1182/blood-2018-99-115358

Published: 2018

Journal Articles

Ruxolitinib Can Lead to Weight Gain in Patients with Myeloproliferative Neoplasms By Uncoupling Feeding from Central Leptin Signaling Via JAK2/STAT3

Spencer Krichevsky, BS, Pouneh Kermani, PhD, Nicole Molle, BS, Richard T. Silver, MD, Andrew I. Schafer, MD, Ellen K. Ritchie, MD, Joseph Scandura, MD PhD

Blood (2018) 132 (Supplement 1): 4284.

https://doi.org/10.1182/blood-2018-99-119542

Published: 2018

Journal Articles

Development of an Automated Tool for Assessing Response in Patients with Polycythemia Vera

Evan Sholle, MS, Spencer Krichevsky, BS, Joseph Scandura, MD PhD, Claudia Sosner, BA, Niamh Savage, BA, Thomas R Campion, Jr., PhD

Blood (2018) 132 (Supplement 1): 5462.

https://doi.org/10.1182/blood-2018-99-119628

Published: 2018

Journal Articles

Clinical and Laboratory Benefits of Early Initiation of Hydroxyurea with Pharmacokinetic Guided Dosing for Young Children with Sickle Cell Anemia

Patrick T. McGann, MD, Omar Niss, MD, Min Dong, PhD, Anu Marahatta, PhD, Tomoyuki Mizuno, PhD, Karen Kalinyak, MD, Theodosia A. Kalfa, MD PhD, Punam Malik, MD, Charles T. Quinn, MD, Russell E. Ware, MD PhD, Alexander A. Vinks, PharmD, PhD FCP

Blood (2018) 132 (Supplement 1): 507.

https://doi.org/10.1182/blood-2018-99-112909

Published: 2018

Journal Articles

Initial Therapy of Polycythemia Vera (PV) with Interferon Alfa (rIFNa) Compared to Hydroxyurea (HU) or Phlebotomy Only (PHL-O) Is Associated with a Lower Risk of Secondary Myelofibrosis

Ghaith Abu-Zeinah, MD, Spencer Krichevsky, BS, Claudia Sosner, BA, Niamh Savage, BA, Joseph Scandura, MD PhD, Richard T. Silver, MD

Blood (2018) 132 (Supplement 1): 4316.

https://doi.org/10.1182/blood-2018-99-115520

Published: 2018

Journal Articles

Gene Therapy for Sickle Cell Anemia Using a Modified Gamma Globin Lentivirus Vector and Reduced Intensity Conditioning Transplant Shows Promising Correction of the Disease Phenotype

Blood (2018) 132 (Supplement 1): 1021.

https://doi.org/10.1182/blood-2018-99-119591

Published: 2018

Journal Articles

Evaluation of Phenotype-Genotype Correlation in Two Common PIEZO1 Mutations p.R2456H and p.L2495_E2495dup

Mary Risinger, PhD, Vandy Black, MDMSc, Loan Hsieh, MD, Renee C. Prins, MD, Jill Menell, MD, Mohamad Badawi, MD, Cynthia Rutherford, MD, Karen L. Bride, MD PhD, Omar Niss, MD, Charles T. Quinn, MD, Katie Giger Seu, PhD, Wenying Zhang, MDPhD, Theodosia A. Kalfa, MD PhD

Blood (2018) 132 (Supplement 1): 1040.

https://doi.org/10.1182/blood-2018-99-117299

Published: 2018

Journal Articles

Critical Evaluation of Who 2016 Criteria for the Diagnosis of Polycythemia Vera: Distinction from JAK2V617+ Essential Thrombocythemia

Richard T Silver, MD, Spencer Krichevsky, BS

Blood (2017) 130 (Supplement 1): 4181.

https://doi.org/10.1182/blood.V130.Suppl_1.4181.4181

Published: 2017

Journal Articles

Results Update from the DRIVE PK Study: Effects of AG-348, a Pyruvate Kinase Activator, in Patients with Pyruvate Kinase Deficiency

Blood (2017) 130 (Supplement 1): 2194.

https://doi.org/10.1182/blood.V130.Suppl_1.2194.2194

Published: 2017

Journal Articles

Insurance Design and Out-of-Pocket (OOP) Costs: a Comparison of Oral and Intravenous (IV) Treatment Plans for Chronic Lymphocytic Leukemia (CLL) in the Era of the Affordable Care Act (ACA)

Andrea Sitlinger, MD, Rishi Sachdev, David Anderson, BS/MS, S. Yousuf Zafar, MD MHS

Blood (2017) 130 (Supplement 1): 4680.

https://doi.org/10.1182/blood.V130.Suppl_1.4680.4680

Published: 2017

Journal Articles

Chromosome 6 Loss-of-Heterozygosity in Pre-Transplant Blood Samples of Patients with Severe Aplastic Anemia Is Associated with Lower Risk of Acute Graft- Versus -Host Disease

Shahinaz M Gadalla, MD PhD, Weiyin Zhou, MS, Tao Wang, PhD, Yoshitaka Zaimoku, MD, Shinji Nakao, MD PhD, Laurie Burdette, PhD, Amanda Willis, BS, Medhat Askar, MD PhD, Michael Haagenson, MS, Meredith Yeager, PhD, Youjin Wang, Stephen R. Spellman, Stephen J Chanock, MD, Stephanie J. Lee, MD PhD, Sharon A Savage, MD

Blood (2017) 130 (Supplement 1): 4479.

https://doi.org/10.1182/blood.V130.Suppl_1.4479.4479

Published: 2017

NARROW

Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia

Recombinant Interferon-α Reduces Thrombotic Events in Patients with Polycythemia Vera

Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib

Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival

Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings

Impact of Bone Marrow Fibrosis Grade in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis. a Study of the Mysec Group

Disease Phenotype and Clonal Amplification in Calreticulin del52 and ins5 Knock-in Mice Are Dependent on the Type of Mutations and Gene Dosage

Chitinase 3-like 1 Produced By Fibrocytes Promotes Myelofibrosis

Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX

Tet2 Deficiency in Macrophages Undermines Heart Repair after Infarction

Ruxolitinib Can Lead to Weight Gain in Patients with Myeloproliferative Neoplasms By Uncoupling Feeding from Central Leptin Signaling Via JAK2/STAT3

Development of an Automated Tool for Assessing Response in Patients with Polycythemia Vera

Clinical and Laboratory Benefits of Early Initiation of Hydroxyurea with Pharmacokinetic Guided Dosing for Young Children with Sickle Cell Anemia

Initial Therapy of Polycythemia Vera (PV) with Interferon Alfa (rIFNa) Compared to Hydroxyurea (HU) or Phlebotomy Only (PHL-O) Is Associated with a Lower Risk of Secondary Myelofibrosis

Gene Therapy for Sickle Cell Anemia Using a Modified Gamma Globin Lentivirus Vector and Reduced Intensity Conditioning Transplant Shows Promising Correction of the Disease Phenotype

Evaluation of Phenotype-Genotype Correlation in Two Common PIEZO1 Mutations p.R2456H and p.L2495_E2495dup

Critical Evaluation of Who 2016 Criteria for the Diagnosis of Polycythemia Vera: Distinction from JAK2V617+ Essential Thrombocythemia

Results Update from the DRIVE PK Study: Effects of AG-348, a Pyruvate Kinase Activator, in Patients with Pyruvate Kinase Deficiency

Insurance Design and Out-of-Pocket (OOP) Costs: a Comparison of Oral and Intravenous (IV) Treatment Plans for Chronic Lymphocytic Leukemia (CLL) in the Era of the Affordable Care Act (ACA)

Chromosome 6 Loss-of-Heterozygosity in Pre-Transplant Blood Samples of Patients with Severe Aplastic Anemia Is Associated with Lower Risk of Acute Graft- Versus -Host Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only